A prospective, randomized, open label, clinical study to evaluate safety and effectiveness of novel methylcobalamin nasal spray compared to oral methylcobalamin in the treatment of subjects with vitamin B12 deficiency.

Dr Arunansu Talukdar0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Vitamin B12 level < 200 pg/mL (148 pmol/L)
•Above the age of 18 years
•Willing & able to comply with study requirements, e.g. usage of medicines as per protocol, willing to adhere with study visit schedule and willing to fill Patient Diary, as indicated by written informed consent provided by the patient.
•Study population will be EITHER any of the following in either gender:
•General Population
•Patients who are on Metformin (>=1000mg/day) therapy for >= 4 months
•Anaemic patients having hemoglobin level of < 9 g/dL
•Chronic Alcoholic Patients as per DSM V criteria
•Patients on PPI therapy for >= 6 months
•Patients who have undergone Bariatric Surgery (e.g. RYGB surgery/ Mini gastric bypass surgery/ Sleeve Gastrectomy/ Sleeve Gastroplasty etc) OR Gastric Surgery for any indication.
•OR Study population will be any of the following in female population:
•Women on Oral Contraceptive Pills
•Women with Poly Cystic Ovarian Disease(PCOD)
•on Metformin
•If women of childbearing potential are recruited they must be non-pregnant (supported by negative urine pregnancy test at screening), and be willing to maintain reliable birth control throughout the study.

•Lactating Women
•Patients with known hypersensitivity or allergies to cobalt and/or vitamin B12 or any component of the study medication.
•Patients with any significant nasal pathology, or having chronic nasal symptoms or nasal allergies or upper respiratory tract infections.
•Patient using any other nasal medication/device.
•Patients having a known diagnosis of severe renal impairment or renal failure. Patients on treatment with drugs which interfere with vitamin B12 assay.
•Participated in any clinical trial within last 30 days at the time of screening.
•Any disorder or condition that in the opinion of investigator would prohibit study participation or affect study outcome.

发起方

Dr Arunansu Talukdar